Company intelligence / Profile preview

Coripharma

Hafnarfjordur, Iceland

Ownership: Private
Employees: ~200
Development stage: Commercial

Overview

Coripharma is an active European generic pharmaceutical company based in Iceland. Since its founding in 2018, it has developed and launched several own-developed generic products, with over 20 dossiers available for out-licensing. The company has demonstrated strong growth, recently achieving record sales revenue and expanding its workforce to over 200 employees. It holds a renewed GMP license following successful regulatory audits.

Therapeutic areas: Hematology
Modalities: Small molecule (generic drugs)
Industry: Biotech

Drug pipeline

4 assets

ruxolitinib

Commercial

Indications: Primary myelofibrosis

3 more assets in the full pipeline.

Request access →

Partnerships

Out-license agreements with other generic pharmaceutical companies for distribution of their developed products/dossiers

Beyond the preview

Go deeper on Coripharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coripharma.

Explore the full profile